Advertisement


Michael Gnant, MD, on Hormone Receptor–Positive Breast Cancer: Results From the ABCSG-18 Trial

2015 San Antonio Breast Cancer Symposium

Advertisement

Michael Gnant, MD, of the Medical University of Vienna, discusses a study in which denosumab was added to adjuvant aromatase inhibitor therapy to improve disease-free survival in postmenopausal patients with early-stage, hormone receptor–positive breast cancer (Abstract S2-02).



Related Videos

Breast Cancer

Lori Pierce, MD, on Breast Cancer Radiotherapy: Late Side Effects

Lori J. Pierce, MD, of the University of Michigan Health System, discusses findings on second cancer incidence and non-breast cancer mortality among 40,000 women in 75 clinical tri...

Breast Cancer

Hans Wildiers, MD, PhD on the TH3RESA Study: Final OS Results

Hans Wildiers, MD, PhD, of the University Hospitals, Leuven, discusses this phase III study on the use of ado-trastuzumab emtansine vs treatment of physician’s choice in previously...

Breast Cancer

Andrew Seidman, MD, and Hope Rugo, MD: Less is More: Scaling Back Breast Cancer Treatment

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss findings on de-escalat...

Breast Cancer

Andrew Seidman, MD, and Eric Winer, MD, on Triple-Negative Breast Cancer: Results of the CALGB Alliance Trial

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Eric P. Winer, MD, of the Dana-Farber Cancer Institute, discuss the results of this study that s...

Breast Cancer
Cost of Care

Benjamin D. Smith, MD, on Mastectomy vs Lumpectomy: Complications and Costs

Benjamin D. Smith, MD, of the MD Anderson Cancer Center, discusses the higher complication rates and economic burdens of mastectomy plus reconstruction vs lumpectomy plus radiation...

Advertisement

Advertisement



Advertisement